Biotech News
Related news
Madrigal
MASH-Focused Biopharmaceutical Company Madrigal Pharmaceuticals is focused on metabolic dysfunction-associated steatohepatitis, a progressive liver disease that can lead to cirrhosis, liver failure, cancer, and transplantation. The company is building a specialized commercial and clinical-development organization around therapies that...
Recent company news
MDGLMadrigal2026-11-18 21:04 EST
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
MDGLMadrigal2026-11-13 13:00 EST
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
MDGLMadrigal2026-11-05 15:00 EST
Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra
MDGLMadrigal2026-11-03 12:00 EST
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
MDGLMadrigal2026-10-27 12:00 EST
Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
Stock data
- Close
- 396.74 USD
- Market cap
- 10.44B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
